Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (DE:BO1)
FRANKFURT:BO1
BioCryst (BO1) Stock Price & Analysis
1 Followers
BO1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.91 - €8.21
Previous Close€4.01
Volume0.00
Average Volume (3M)758.00
Market Cap
€843.03M
Enterprise Value€775.90M
Total Cash (Recent Filing)$388.99M
Total Debt (Recent Filing)$317.11M
Price to Earnings (P/E)N/A
Beta0.42
Next Earnings
May 06, 2024EPS Estimate
-€0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding206,149,929
10 Day Avg. Volume360
30 Day Avg. Volume758
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.91
Price to Sales (P/S)2.49
Price to Cash Flow (P/CF)-24.30
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
€14.22Price Target Upside266.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
BioCryst News
Bulls Say, Bears Say
Bulls Say
Drug Development And Sales PotentialBioCryst's initiation of a proof-of-concept trial for its oral factor D inhibitor in PNH patients highlights the company's commitment to addressing complement-mediated diseases and signals potential for significant growth in the drug's value.
Financial Performance And Market ConfidenceAnalyst maintains a Market Outperform rating on BioCryst, bolstered by strong Orladeyo sales growth and management's guidance towards profitability, painting a promising picture for investors.
Pipeline Expansion And Market OpportunityBioCryst's development of new preclinical candidates and the strategic expansion of Orladeyo's label for pediatric use underscore the company's potential for sustained growth and market expansion.
Bears Say
Analyst AdjustmentAnalyst has lowered the price target for BioCryst, reflecting adjustments in their financial valuation.
Earnings Guidance2024 guidance of $380-400M is slightly below consensus of $404M.
Sales ForecastManagement does not expect much progress on the Medicare population in 2024 affecting Orladeyo sales.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.79% Other Institutional Investors
98.21% Public Companies and
Individual Investors
BO1 FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was €3.91 and its highest was €8.21 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Currently, no data Available
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is May 06, 2024 which is in 8 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Feb 26, 2024. The company reported -€0.29 earnings per share for the quarter, missing the consensus estimate of -€0.23 by -€0.06.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is -€0.2.
How many shares outstanding does Biocryst Pharmaceuticals have?
Currently, no data Available
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of -€0.29 in its last earnings report, missing expectations of -€0.23. Following the earnings report the stock price went up 1.689%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Among the largest hedge funds holding Biocryst Pharmaceuticals’s share is Baker Bros Advisors LP. It holds Biocryst Pharmaceuticals’s shares valued at 61M.
---
BioCryst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.22 (266.96% Upside)
€14.22 (266.96% Upside)
Blogger Sentiment
Bullish
DE:BO1 Sentiment 95%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
---
BO1 Company Deck
---
BO1 Earnings Call
Q4 2024
0:00 / 0:00
---
BO1 Stock 12 Months Forecast
Average Price Target
€14.22
▲(266.96% Upside)
Technical Analysis
Best Analysts Covering BO1
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
+39.45%
reiterated a buy rating 2 months ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +39.45% per trade.
---